EPISODE · Mar 18, 2025 · 2 MIN
Analyzing Johnson & Johnson's Steady Growth, Dividend, and Analyst Outlook
from Johnson & Johnson News Daily · host Inception Point AI
As of the latest update, Johnson and Johnson's stock price is around one hundred sixty-two dollars and twelve cents per share. The trading volume has been notably lower than average, with recent days seeing a significant decline compared to the usual daily volume. For instance, on a recent trading day, the volume was eighty-two percent below the average daily volume of approximately seven million, three hundred thirty-two thousand shares. Recently, Johnson and Johnson reported strong fourth-quarter results for two thousand twenty-four, with a five-point-three percent increase in sales. The company's MedTech segment showed significant growth, driven by electrophysiology products and wound closure solutions. For the full year two thousand twenty-five, Johnson and Johnson expects operational sales to grow between two-point-five and three-point-five percent. In terms of analyst updates, several firms have adjusted their price targets for Johnson and Johnson. Bank of America raised its target from one hundred fifty-nine dollars to one hundred seventy-one dollars, while Royal Bank of Canada maintained an outperform rating with a target of one hundred eighty-one dollars. Citigroup reduced its target from one hundred eighty-five dollars to one hundred seventy-five dollars but maintained a buy rating. Overall, the consensus among analysts is a moderate buy with a target price of approximately one hundred seventy-one dollars and thirty-three cents. Johnson and Johnson also recently announced a quarterly dividend of one dollar and twenty-four cents per share, reflecting a yield of approximately three-point-zero-four percent. The company's financial health and consistent dividend payouts make it an attractive option for investors seeking stability. Despite the recent low trading volume, Johnson and Johnson remains a significant player in the healthcare sector, with a market capitalization of nearly three hundred ninety-four billion dollars. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.
What this episode covers
As of the latest update, Johnson and Johnson's stock price is around one hundred sixty-two dollars and twelve cents per share. The trading volume has been notably lower than average, with recent days seeing a significant decline compared to the usual daily volume. For instance, on a recent trading day, the volume was eighty-two percent below the average daily volume of approximately seven million, three hundred thirty-two thousand shares. Recently, Johnson and Johnson reported strong fourth-quarter results for two thousand twenty-four, with a five-point-three percent increase in sales. The company's MedTech segment showed significant growth, driven by electrophysiology products and wound closure solutions. For the full year two thousand twenty-five, Johnson and Johnson expects operational sales to grow between two-point-five and three-point-five percent. In terms of analyst updates, several firms have adjusted their price targets for Johnson and Johnson. Bank of America raised its target from one hundred fifty-nine dollars to one hundred seventy-one dollars, while Royal Bank of Canada maintained an outperform rating with a target of one hundred eighty-one dollars. Citigroup reduced its target from one hundred eighty-five dollars to one hundred seventy-five dollars but maintained a buy rating. Overall, the consensus among analysts is a moderate buy with a target price of approximately one hundred seventy-one dollars and thirty-three cents. Johnson and Johnson also recently announced a quarterly dividend of one dollar and twenty-four cents per share, reflecting a yield of approximately three-point-zero-four percent. The company's financial health and consistent dividend payouts make it an attractive option for investors seeking stability. Despite the recent low trading volume, Johnson and Johnson remains a significant player in the healthcare sector, with a market capitalization of nearly three hundred ninety-four billion dollars. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.
NOW PLAYING
Analyzing Johnson & Johnson's Steady Growth, Dividend, and Analyst Outlook
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m